2025 Results Reveal €1.1B Loss and Weakened Outlook
BioNTech disclosed its full-year 2025 financial results on March 10, 2026, revealing a net loss of €1.1 billion on total revenues of €2.9 billion. The performance translates to a diluted loss per share of €4.70 ($5.31). Despite the loss, the company highlighted its strong financial position, holding €17.2 billion in cash, cash equivalents, and security investments, which it plans to use to de-risk its strategic execution.
The outlook for 2026 points to continued financial pressure. BioNTech guided for total revenues to decline to a range of €2.0 billion to €2.3 billion. Simultaneously, the company plans significant operational spending, with adjusted research and development expenses forecasted between €2.2 billion and €2.5 billion, and administrative expenses between €700 million and €800 million.
Founders Sahin and Türeci to Exit for New mRNA Venture
In a significant leadership shift, co-founders Ugur Sahin and Özlem Türeci announced their intention to depart by the end of 2026. The duo, renowned for their role in the company's success, will establish a new, independent company dedicated to next-generation mRNA innovations. This move raises questions about BioNTech's long-term innovation capacity and leadership stability, potentially impacting investor confidence.
As its founders prepare their exit, BioNTech is focusing its strategy on its existing drug pipeline. The company stated it is on track for a catalyst-rich year, with six late-stage data readouts expected across its oncology portfolio. It specifically highlighted an increased focus on its PD-L1/VEGF-A bispecific immunomodulator, pumitamig, with plans for eight global Phase 3 clinical trials to be ongoing by the end of the year.
